BioMarin Pharma (BMRN) Tops Q3 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Wall St subdued in choppy trade after big bank earnings, chips slide
- Oil prices ease as US-Russia diesel deal hopes offset Middle East attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $54.31 -1.95%
EPS Growth %: +1,008.3%
Financial Fact:
Net product revenues: 278.26M
Today's EPS Names:
PGR, OMID, ACI, More
EPS Growth %: +1,008.3%
Financial Fact:
Net product revenues: 278.26M
Today's EPS Names:
PGR, OMID, ACI, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of $0.12, $0.20 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $776 million versus the consensus estimate of $782.3 million.
GUIDANCE:
BioMarin Pharma sees FY2025 EPS of $4.40-$4.55, versus the consensus of $3.34. BioMarin Pharma sees FY2025 revenue of $3.15-3.2 billion, versus the consensus of $3.17 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman’s CEO Solomon says to watch political volatility around data centers
- IREN shares drop as Anthropic deal enthusiasm fades
- Piper says this stock is a "solid bounce-back candidate"
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
